The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer
Open accessAbstract
The relationships between diabetes and pancreatic ductal adenocarcinoma (PDAC) are complex. Longstanding type 2 diabetes (T2DM) is a risk factor for pancreatic cancer, but increasing epidemiological data point to PDAC as also a cause of diabetes due to unknown mechanisms. New-onset diabetes is of particular interest to the oncology community as the differentiation of new-onset diabetes caused by PDAC as distinct from T2DM may allow for earlier diagnosis of PDAC. To address these relationships and raise awareness of the relationships between PDAC and diabetes, a symposium entitled Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer was held at the American Diabetes Association’s 76th Scientific Sessions in June 2016. This article summarizes the data presented at that symposium, describing the current understanding of the interrelationships between diabetes, diabetes management, and pancreatic cancer, and identifies areas where additional research is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A distinguishing feature is concurrent pancreatic exocrine insuf fi ciency (consider screening individuals with acute and chronic pancreatitis for exocrine pancreatic insuf fi ciency by measuring fecal elastase), pathological pancreatic imaging (endoscopic ultrasound, MRI, and computed tomography), and absence of type 1 diabetes -associated autoimmunity (116 -120).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [119]
In the citing paper
“Thus, new-onset diabetes can be considered an early warning sign of pancreatic ductal adenocarcinoma,22”
From Early detection of pancreatic cancer (2020) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166 · cited 1×
“Concomitantly, there is failure to enhance peripheral (predominantly skeletal muscle) glucose utilization, with initially increased insulin levels, as the b-cell attempts to overcome the insulin resistance (9).”
BackgroundWellcome Trust Case Control Consortium, Zeggini, E., Scott, L. J., Saxena, R., Voight, B. F., Marchini, J. L., Hu, T., de Bakker, P. I., Abecasis, G. R., Almgren, P., et al. (2008) · Nature Genetics · doi:10.1038/ng.120 · Cited by 1,864
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
The genetic architecture of type 2 diabetes
Fuchsberger, C., Flannick, J., Teslovich, T. M., Mahajan, A., Agarwala, V., Gaulton, K. J., Ma, C., Fontanillas, P., Moutsianas, L., McCarthy, D. J., et al. (2016) · Nature · doi:10.1038/nature18642 · Cited by 1,051
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826 · cited 2×
“Susceptibility genes that have been identified range from rare mutations in genes associated with cancer syndromes to common SNPs. Designs that include familybased and case-control studies have uncovered mutations in known syndrome-related genes, such as BRCA1, BRCA2, CDKN2A, and CFTR. Next-generation sequencing has i…”
BackgroundObesity and cancer—mechanisms underlying tumour progression and recurrence
Park, J., Morley, T. S., Kim, M. G., Clegg, D. J., & Scherer, P. E. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.94 · Cited by 808
Cited by
Sorted by citations
Items 501–524 of 524
Kaser, S., Hofer, S. E., Kazemi-Shirazi, L., Stulnig, T., Winhofer-Stöckl, Y., Resl, M., Ress, C., Sourij, H., Aberer, F., Treiber, G. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02653-0
Kandemir, H., Kahraman, D. S., Aktas, S., Ünal, O. Ü., & Cagiral, S. (2026) · Discover Oncology · doi:10.1007/s12672-026-05195-7
Lipid Metabolism, Lipogenesis, and Resistance to Third Generation EGFR‐TKIs
Luo, W., Wang, Z., Ma, G., Wang, S., Chen, X., & Liao, Y. (2026) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70274
Yang, R., Sun, Y., An, R., Chen, X., Pang, X., Zhang, J., Wang, J., Han, J., Ma, T., Wang, M., et al. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01456-2
Choi, S. A., & Hong, S.-H. (2026) · Genes & Genomics · doi:10.1007/s13258-026-01781-9
Wang, W., ZHAO, Y., Jiang, S., Zhou, Y., Yang, Q., Li, D., Jiang, Y., Chen, H., Tang, X. Y., Ren, L., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04395-z
Self-citationAcinar-ductal metaplasia in pancreatitis and pancreatic ductal adenocarcinoma
Zhang, X., Zhao, Y., Qin, C., Li, Z., Xie, Y., Yan, Y., Li, T., Huang, L., Shi, H., & Wang, W. (2026) · Cellular Oncology · doi:10.1007/s13402-026-01251-0
Diabetes mellitus und Pankreaskarzinom: Eine komplexe Beziehung
Adamek, H. E., & Sontag, I. (2026) · Gastro-News · doi:10.1007/s15036-026-4051-x
Rezagholizadeh, F., Rokn, S., FakherBaheri, M., Taherian, Z., Rostami, H., Azmoudeh-Ardalan, F., Rahimi, M., Wadji, M. B., Kashanizadeh, A., Eghtedari, S., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05158-3
Simon, L., Mire, M., McTernan, P. M., Gallegos, E. M., Coleman, L., Siggins, R. W., Caro, A., Baker, C. L., & Molina, P. E. (2026) · Function · doi:10.1152/function.033.2026
Shah, R., & Vora, T. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101786
Postoperative blood glucose levels: A predictor of poor survival in resected pancreatic cancer
Liu, Y., Liao, Y., xiao, Z., Li, Y., Zhang, N., Shi, Y., Song, Y., Wang, X., Ni, Q., Pawlik, T. M., et al. (2026) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000264
Aydın, O., Korkmaz, Y. Y., ALTAY, M., Kudaş, İ., Baş, S., Bostancı, Ö., & Kınacı, E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176693
Zhang, T., Li, X., Guo, Y., Zeng, J., Xu, M., & Wang, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1942873
Predicting Pancreatogenic Disease Progression Via Hybrid Physiological and Neural ODE Modeling
Adamic, M., & Lu, W. (2026) · Lecture notes on data engineering and communications technologies · doi:10.1007/978-3-032-29430-2_18
Masamune, A., Tanaka, Y., Tanaka, Y., Takikawa, T., Sekino, Y., Matsumoto, R., Asai, Y., Katagiri, H., Ueki, K., & Kikuta, K. (2026) · Cancers · doi:10.3390/cancers18182995
Dong, Z., Zhou, T., Ma, S., Chen, X., & Lai, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1945735
Zhu, H., Fan, H., Yang, W., Gao, S., Chang, J., Zong, G., Zhuang, Y., Abudukeranmu, A., Jia, X., Zhu, Y., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-339722
Camacho-Flores, L. M., Alvarez, A., Vazquez, R. B., Benet, P., García, C. B. A., & del Rio, M. M. (2026) · Cureus · doi:10.7759/cureus.117696
Mishra, P., Pramodkumar, T. A., Pradhan, B., Ghosh, U., Mishra, P. K., Dash, P., Anjana, R. M., Patra, S. K., & Mohan, V. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01926-9
Roosa, S., Aaltonen, P., Mustonen, H. K., Sund, M., & Hanna, S. (2026) · Cancer Medicine · doi:10.1002/cam4.72380
Rodrigues, R., Soares, R. A., Vasconcelos, M. H., & Xavier, C. P. R. (2026) · Pancreatology · doi:10.1016/j.pan.2026.10.025
Wu, J., Jiang, T., Li, X., Xie, D., & Xie, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1995824
Yang, J., Wang, X., Liu, Y., Wang, Y., Pandol, S. J., Lv, Y., Li, X., & Li, L. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113615
Metadata
- Authors
- Andersen, D. K., Korc, M., Petersen, G. M., Eibl, G., Li, D., Rickels, M. R., Chari, S. T., & Abbruzzese, J. L.
- Affiliations
- National Institutes of Health (US)
- Indiana University Indianapolis (US)
- Mayo Clinic (US)
- University of California, Los Angeles (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Pennsylvania (US)
- Duke University (US)
- Corresponding author
- Abbruzzese, James L.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-04-13
- Volume
- 66
- Issue
- 5
- Pages
- 1103-1110
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC5399609
- OpenAlex
- W2615250694
- Cited by
- 516
- References
- 50
- Citations by year
- 2026: 43 · 2025: 55 · 2024: 78 · 2023: 71 · 2022: 79 · 2021: 61 · 2020: 59 · 2019: 40 · 2018: 24 · 2017: 5
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic ductal adenocarcinoma, type 2 diabetes, pancreatic diabetes, new-onset diabetes, pancreatic cancer risk factors, diabetes management, early cancer detection
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Inflammation, Obesity, Pancreatic Neoplasms, Risk Factors, Causality, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, Pancreatitis, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
